News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,091 Results
Type
Article (40878)
Company Profile (267)
Press Release (679936)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204654)
Career Advice (2022)
Deals (35531)
Drug Delivery (110)
Drug Development (81378)
Employer Resources (173)
FDA (16401)
Job Trends (14941)
News (346354)
Policy (32721)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2565)
Accelerated approval (31)
Adcomms (24)
Allergies (137)
Alliances (49575)
ALS (167)
Alzheimer's disease (1658)
Antibody-drug conjugate (ADC) (305)
Approvals (16666)
Artificial intelligence (500)
Autoimmune disease (143)
Automation (37)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (187)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (55)
Breast cancer (631)
Cancer (4749)
Cardiovascular disease (395)
Career advice (1707)
Career pathing (35)
CAR-T (275)
CDC (44)
Celiac Disease (2)
Cell therapy (728)
Cervical cancer (36)
Clinical research (69490)
Collaboration (1666)
Company closure (4)
Compensation (1138)
Complete response letters (52)
COVID-19 (2709)
CRISPR (87)
C-suite (810)
Cystic fibrosis (143)
Data (6144)
Decentralized trials (2)
Denatured (25)
Depression (130)
Diabetes (495)
Diagnostics (6669)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (241)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (225)
Earnings (90035)
Editorial (55)
Employer branding (21)
Employer resources (151)
Events (117170)
Executive appointments (958)
FDA (19474)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1444)
Gene editing (191)
Generative AI (42)
Gene therapy (581)
GLP-1 (966)
Government (4651)
Grass and pollen (6)
Guidances (383)
Healthcare (18867)
HIV (55)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (244)
Immuno-oncology (53)
Indications (103)
Infectious disease (2967)
Inflammatory bowel disease (186)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (242)
Interviews (315)
IPO (16638)
IRA (49)
Job creations (3641)
Job search strategy (1427)
JPM (56)
Kidney cancer (15)
Labor market (83)
Layoffs (545)
Leadership (30)
Legal (7948)
Liver cancer (91)
Longevity (14)
Lung cancer (638)
Lymphoma (371)
Machine learning (42)
Management (59)
Manufacturing (776)
MASH (163)
Medical device (13753)
Medtech (13805)
Mergers & acquisitions (19950)
Metabolic disorders (1254)
Multiple sclerosis (155)
NASH (16)
Neurodegenerative disease (307)
Neuropsychiatric disorders (86)
Neuroscience (2864)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4508)
Now hiring (65)
Obesity (590)
Opinion (256)
Ovarian cancer (164)
Pain (195)
Pancreatic cancer (222)
Parkinson's disease (279)
Partnered (33)
Patents (486)
Patient recruitment (469)
Peanut (55)
People (58804)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21667)
Phase 2 (30583)
Phase 3 (22789)
Pipeline (5071)
Policy (278)
Postmarket research (2564)
Preclinical (9191)
Press Release (64)
Prostate cancer (234)
Psychedelics (47)
Radiopharmaceuticals (277)
Rare diseases (813)
Real estate (5953)
Recruiting (69)
Regulatory (24409)
Reports (51)
Research institute (2383)
Resumes & cover letters (351)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (146)
Series A (237)
Series B (184)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3612)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (54)
Vaccines (985)
Venture capital (86)
Weight loss (377)
Women's health (87)
Worklife (18)
Date
Today (14)
Last 7 days (591)
Last 30 days (2198)
Last 365 days (29785)
2026 (2811)
2025 (30175)
2024 (35217)
2023 (40076)
2022 (51174)
2021 (55713)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (305)
Arkansas (13)
Asia (39186)
Australia (6404)
California (11153)
Canada (3249)
China (1082)
Colorado (471)
Connecticut (469)
Delaware (332)
Europe (84414)
Florida (1660)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (850)
India (62)
Indiana (513)
Iowa (22)
Japan (417)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1369)
Massachusetts (7985)
Michigan (319)
Minnesota (621)
Mississippi (5)
Missouri (125)
Montana (31)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2965)
New Mexico (28)
New York (2939)
North Carolina (1433)
North Dakota (8)
Northern California (5435)
Ohio (329)
Oklahoma (21)
Oregon (41)
Pennsylvania (2252)
Puerto Rico (22)
Rhode Island (47)
South America (1107)
South Carolina (65)
South Dakota (1)
Southern California (4339)
Tennessee (172)
Texas (1718)
United States (39529)
Utah (333)
Vermont (1)
Virginia (256)
Washington D.C. (81)
Washington State (913)
West Virginia (4)
Wisconsin (106)
Wyoming (2)
721,091 Results for "altimmune inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
MASH
Altimmune Poised for $1B+ Opportunity as MASH Drug Aces Phase IIb
Altimmune’s pemvidutide showed “class-leading signals” in non-invasive assessments and has “potentially best-in-class tolerability,” according to analysts at H.C. Wainwright.
November 12, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
January 30, 2026
·
4 min read
Press Releases
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
January 28, 2026
·
4 min read
Press Releases
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
January 5, 2026
·
6 min read
Press Releases
Altimmune Announces CEO Transition and Succession Plan
December 2, 2025
·
6 min read
MASH
Altimmune Nosedives on Mixed Mid-Stage MASH Data for GLP-1/Glucagon Drug
Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed 53% in the aftermath of the readout.
June 27, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 27, 2025
·
1 min read
Press Releases
Altimmune to Participate in Two Upcoming November 2025 Investor Conferences
November 6, 2025
·
1 min read
Press Releases
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
November 6, 2025
·
12 min read
Press Releases
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
December 22, 2025
·
9 min read
1 of 72,110
Next
